Treatment in myositis

Nature Reviews Rheumatology

Volumn 14, Issue 5, 2018, Pages 279-289

  Oddis, Chester V ^a   Aggarwal, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANAKINRA; AZATHIOPRINE; BIOLOGICAL PRODUCT; CALCINEURIN INHIBITOR; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL FACTOR;

ARTHRITIS; AUTOIMMUNE DISEASE; DERMATOMYOSITIS; DYSPHAGIA; EXERCISE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MYOSITIS; PHENOTYPE; PRIORITY JOURNAL; RARE DISEASE; RASH; REVIEW; CLINICAL TRIAL (TOPIC); DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BIOLOGICAL FACTORS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MYOSITIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85045908516     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2018.42     Document Type: Review

References (119)

1. Rider, L. G. et al. Update on outcome assessment in myositis. Nat. Rev. Rheumatol. https://doi. org/10.1038/nrrheum.2018.33 (2018).
2. Greenberg, S. A. et al. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 35, 17-23 (2007).
3. Greenberg, S. A. et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57, 664-678 (2005).
4. Bilgic, H. et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 60, 3436-3446 (2009).
5. Kurasawa, K. et al. Activation of pulmonary T cells in corticosteroid-resistant and-sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin. Exp. Immunol. 129, 541-548 (2002).
6. Yamadori, I. et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Rheumatol. Int. 21, 89-93 (2001).
7. Katagiri, A. et al. Decrease in CD4+CD25+ and CD8+CD28+ T cells in interstitial pneumonitis associated with rheumatic disease. Mod. Rheumatol. 18, 562-569 (2008).
8. Notarnicola, A. et al. Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies. Reumatismo 66, 215-223 (2014).
9. Shen, H. et al. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand. J. Rheumatol. 40, 217-220 (2011).
10. Tournadre, A., Lenief, V. & Miossec, P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 62, 2144-2151 (2010).
11. Nagaraju, K. Update on immunopathogenesis in inflammatory myopathies. Curr. Opin. Rheumatol. 13, 461-468 (2001).
12. Englund, P. et al. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am. J. Pathol. 159, 1263-1273 (2001).
13. Nagaraju, K. et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 52, 1824-1835 (2005).
14. Lightfoot, A. P. et al. In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness? Ann. Rheum. Dis. 74, 1340-1346 (2015).
15. Catania, A. et al. The melanocortin system in control of inflammation. ScientificWorldJournal 10, 1840-1853 (2010).
16. Levine, T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des. Devel. Ther. 6, 133-139 (2012).
17. Patel, A., Seely, G. & Aggarwal, R. Repository corticotropin injection for treatment of idiopathic inflammatory myopathies. Case Rep. Rheumatol. 2016, 9068061 (2016).
18. Aggarwal, R. et al. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212047 (2017).
19. Joffe, M. M. et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am. J. Med. 94, 379-387 (1993).
20. Newman, E. D. & Scott, D. W. The use of low-dose methotrexate in the treatment of pollymyositis and dermatomyositis. J. Clin. Rheumatol 1, 99-102 (1995).
21. Ruperto, N. et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387, 671-678 (2016).
22. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00651040 (2016).
23. Joffe, M. M. et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azaathioprine, and methotrexate and a comparison of their efficacy. Am. J. Med. 94, 379-387 (1993).
24. Bunch, T. W. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 24, 45-48 (1981).
25. Bunch, T. W. et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann. Intern. Med. 92, 365-369 (1980).
26. Villalba, L. et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 41, 392-399 (1998).
27. Majithia, V. & Harisdangkul, V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 44, 386-389 (2005).
28. Pisoni, C. N. et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology 46, 516-518 (2007).
29. Rowin, J. et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66, 1245-1247 (2006).
30. Schneider, C. et al. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 25, 286-288 (2002).
31. Danieli, M. G. et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun. Rev. 9, 124-127 (2009).
32. Oddis, C. V. et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353, 1762-1763 (1999).
33. Mitsui, T. et al. The effects of FK506 on refractory inflammatory myopathies. Acta Neurol. Belg. 111, 188-194 (2011).
34. Lambotte, O. et al. Efficacy of rituximab in refractory polymyositis. J. Rheumatol 32, 1369-1370 (2005).
35. Levine, T. D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 52, 601-607 (2005).
36. Mahler, E. A. et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 50, 2206-2213 (2011).
37. Valiyil, R. et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 62, 1328-1334 (2010).
38. Mok, C. C., Ho, L. Y. & To, C. H. Rituximab for refractory polymyositis: an open-label prospective study. J. Rheumatol. 34, 1864-1868 (2007).
39. Chung, L., Genovese, M. C. & Fiorentino, D. F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch. Dermatol. 143, 763-767 (2007).
40. Oddis, C. V. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 65, 314-324 (2013).
41. Rider, L. G. et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 50, 2281-2290 (2004).
42. Aggarwal, R. et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 66, 740-749 (2014).
43. Iannone, F. et al. Use of etanercept in the treatment of dermatomyositis: a case series. J. Rheumatol. 33, 1802-1804 (2006).
44. Muscle Study, G. A randomized, pilot trial of etanercept in dermatomyositis. Ann. Neurol. 70, 427-436 (2011).
45. Anandacoomarasamy, A., Howe, G. & Manolios, N. Advanced refractory polymyositis responding to infliximab. Rheumatology 44, 562-563 (2005).
46. Efthimiou, P., Schwartzman, S. & Kagen, L. J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann. Rheum. Dis. 65, 1233-1236 (2006).
47. Hengstman, G. J. et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur. Neurol. 50, 10-15 (2003).
48. Selva-O'Callaghan, A. et al. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology 43, 1196-1197 (2004).
49. Hengstman, G. J., F. H. van den Hoogen & van Engelen, B. G. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur. Neurol. 52, 61-63 (2004).
50. Dastmalchi, M. et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 67, 1670-1677 (2008).
51. Schiffenbauer, A. et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin. Arthritis Rheum. https://doi.org/10.1016/j. semarthrit.2017.10.010 (2017).
52. Ishikawa, Y. et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin. Rheumatol. 29, 563-566 (2010).
53. Klein, R. et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch. Dermatol. 146, 780-784 (2010).
54. Riolo, G. & Towheed, T. E. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J. Rheumatol. 39, 192-194 (2012).
55. Riley, P. et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 47, 877-880 (2008).
56. Narazaki, M. et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology 50, 1344-1346 (2011).
57. Kondo, M. et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology 53, 1907-1908 (2014).
58. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02043548 (2017).
59. Aggarwal, R. et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative initiative. Arthritis Rheumatol. 69, 898-910 (2017).
60. Arabshahi, B. et al. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J. Pediatr. 160, 520-522 (2012).
61. Kerola, A. M. & Kauppi, M. J. Abatacept as a successful therapy for myositis-a case-based review. Clin. Rheumatol. 34, 609-612 (2015).
62. Maeshima, K. et al. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology 53, 379-380 (2014).
63. Musuruana, J. L. & Cavallasca, J. A. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 78, 431-432 (2011).
64. Tjarnlund, A. et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann. Rheum. Dis. 77, 55-62 (2018).
65. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02971683 (2018).
66. Zong, M. et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann. Rheum. Dis. 73, 913-920 (2014).
67. Dalakas, M. C. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993-2000 (1993).
68. Cherin, P. et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 46, 467-474 (2002).
69. Miyasaka, N. et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod. Rheumatol. 22, 382-393 (2012).
70. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02728752 (2018).
71. Danieli, M. G. et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun. Rev. 10, 144-149 (2011).
72. Alexanderson, H. Physical exercise as a treatment for adult and juvenile myositis. J. Intern. Med. 280, 75-96 (2016).
73. Wiesinger, G. F. et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br. J. Rheumatol. 37, 196-200 (1998).
74. Alexanderson, H., Stenstrom, C. H. & Lundberg, I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology 38, 608-611 (1999).
75. Alexanderson, H. et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand. J. Rheumatol. 29, 295-301 (2000).
76. Munters, L. A. et al. Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis. Arthritis Rheumatol. 68, 1738-1750 (2016).
77. Mammen, A. L. et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 63, 713-721 (2011).
78. Mammen, A. L. & Tiniakou, E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N. Engl. J. Med. 373, 1680-1682 (2015).
79. Morganroth, P. A., Kreider, M. E. & Werth, V. P. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 62, 1496-1501 (2010).
80. Mira-Avendano, I. C. et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/ dermatomyositis. Respir. Med. 107, 890-896 (2013).
81. Fischer, A. et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J. Rheumatol. 40, 640-646 (2013).
82. Tsuchiya, H. et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod. Rheumatol. 24, 694-696 (2014).
83. Douglas, W. W. et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Ann. J. Respir. Crit. Care Med. 164, 1182-1185 (2001).
84. Marie, I. et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 47, 614-622 (2002).
85. Kameda, H. et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J. Rheumatol. 32, 1719-1726 (2005).
86. Mok, C. C., To, C. H. & Szeto, M. L. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand. J. Rheumatol. 32, 181-183 (2003).
87. Yamasaki, Y. et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 46, 124-130 (2007).
88. Schnabel, A. et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin. Arthritis Rheum. 32, 273-284 (2003).
89. Bakewell, C. J. & Raghu, G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 139, 441-443 (2011).
90. Suzuki, Y. et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187, 201-206 (2009).
91. Kotani, T. et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin. Rheumatol. 30, 1021-1028 (2011).
92. Go, D. J. et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol. Int. 36, 125-131 (2016).
93. Wilkes, M. R. et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 52, 2439-2446 (2005).
94. Kurita, T. et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 54, 39-44 (2015).
95. Ochi, S. et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin. Exp. Rheumatol. 23, 707-710 (2005).
96. Takada, K., Nagasaka, K. & Miyasaka, N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38, 383-392 (2005).
97. Keir, G. J. et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19, 353-359 (2014).
98. Andersson, H. et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 54, 1420-1428 (2015).
99. Allenbach, Y. et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS ONE 10, e0133702 (2015).
100. Bauhammer, J. et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response. J. Rheumatol. 43, 1566-1574 (2016).
101. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03215927 (2017).
102. Conway, R. et al. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 66, 803-812 (2014).
103. Conway, R. et al. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ 350, h1269 (2015).
104. Pai, S. B. et al. Hydroxychloroquine-induced erythroderma. Indian J. Pharmacol. 49, 132-134 (2017).
105. Slagel, G. A. & James, W. D. Plaquenil-induced erythroderma. J. Am. Acad. Dermatol. 12, 857-862 (1985).
106. Edge, J. C. et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch. Dermatol. 142, 65-69 (2006).
107. Gelber, A. C., Nousari, H. C. & Wigley, F. M. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. Rheumatol. J. 27, 1542-1545 (2000).
108. Aggarwal, R. et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology 56, 247-254 (2017).
109. Kurtzman, D. J. et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 152, 944-945 (2016).
110. Paik, J. J. & Christopher-Stine, L. A case of refractory dermatomyositis responsive to tofacitinib. Semin. Arthritis Rheum. 46, e19 (2017).
111. Rogers, A. et al. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 69, 1909-1914 (2017).
112. Tayfur, A. C. et al. Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis. Mod. Rheumatol. 25, 615-620 (2015).
113. Pagnini, I. et al. Sodium thiosulfate for the treatment of calcinosis secondary to juvenile dermatomyositis. Clin. Exp. Rheumatol. 32, 408-409 (2014).
114. Smith, G. P., Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease. J. Am. Acad. Dermatol. 69, e146-147 (2013).
115. Marie, I. et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. 62, 1748-1755 (2010).
116. Higgs, B. W. et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann. Rheum. Dis. 73, 256-262 (2014).
117. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03002649 (2018).
118. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02612857 (2017).
119. Moghadam-Kia, S., Oddis, C. V. & Aggarwal, R. Update on the treatment of myositis. Int. J. Clin. Rheumatol. 9, 505-518 (2014).